Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03673228 · ClinicalTrials.gov registry record · NA
Preventing Smoking Relapse After Total Joint Replacement Surgery
A NA study, sponsored by NYU Langone Health.
- Completed
- Registry status
- NA
- Development phase
- 21
- Enrollment target
NCT03673228: Completed NA study, sponsored by NYU Langone Health.
NCT03673228 is a NA study that has completed, run by NYU Langone Health. The registered enrollment target is 21 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03673228, a NA study, has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- NA
- Development phase
- 21 participants
- Enrollment target
Study Summary
Hospitalization for elective knee or hip replacement surgery presents an outstanding opportunity to motivate people to quit smoking, because it provides an opportunity to encourage patients to remain smoke-free as they proactively quit to optimize their surgery outcomes. This study will conduct a comparative effectiveness trial of patients who quit smoking pre-operatively, comparing the current standard of care with a novel comprehensive relapse prevention intervention guided by Marlatt's Relapse Prevention Model.
Primary Outcome
Measured using the modified Dillman method
Interventions
- DRUG Nicotine Replacement Therapy (NRT)
- BEHAVIORAL Standard Treatment Counseling
- BEHAVIORAL Comprehensive Relapse Prevention Intervention
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2019-01-15 |
| Est. Completion | 2021-01-28 |
| Phase | NA |
What the finished NCT03673228 record still lists
NCT03673228 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 21 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 3 interventions - of which Nicotine Replacement Therapy (NRT) is the first listed.
NCT03673228 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03673228 about?
NCT03673228 is a clinical study titled "Preventing Smoking Relapse After Total Joint Replacement Surgery". Hospitalization for elective knee or hip replacement surgery presents an outstanding opportunity to motivate people to quit smoking, because it provides an opportunity to encourage patients to remain smoke-free as they proactively quit to optimize their surgery outcomes. This study will conduct a co...
What is the current status of trial NCT03673228?
This trial is currently completed. It is a NA study. The enrollment target is 21 participants. The study started on 2019-01-15. Estimated completion is 2021-01-28.
What interventions are being tested in trial NCT03673228?
The interventions under investigation include: Nicotine Replacement Therapy (NRT) (DRUG), Standard Treatment Counseling (BEHAVIORAL), Comprehensive Relapse Prevention Intervention (BEHAVIORAL).
Who is sponsoring clinical trial NCT03673228?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03673228's enrollment target sits among peer trials
21 1762nd of 2000 higher than 233 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02447874 · 21 participants · Phase 1
Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease
- NCT03826992 · 21 participants · Phase 1
Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
- NCT04107077 · 21 participants · Phase 2
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
- NCT04158635 · 21 participants · Phase 1
Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI